Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11:933 46. S4.1-24. Gnjidic D, Le Couteur DG, Blyth FM, et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open 2013;3:e002333. S4.1-25. Gray SL, Boudreau RM, Newman AB, et al. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition study. J Am Geriatr Soc. 2011;59:2226 32. S4.1-26. Ho CK, Walker SW. Statins and their interactions with other lipid- modifying medications: safety issues in the elderly. Ther Adv Drug Saf. 2012;3:35 46. S4.1-27. LaCroix AZ, Gray SL, Aragaki A, et al. Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women s Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci. 2008;63:369 75. S4.1-28. Pilotto A, Panza F, Copetti M, et al. Statin treatment and mortality in community-dwelling S4.1-frail older patients with diabetes mellitus: a retrospective observational study. PLoS One 2015:10;e0130946. S4.1-29. Qi K, Reeve E, Hilmer SN, et al. Older people s attitudes regard- ing polypharmacy, statin use and willingness to have statins depre- scribed in Australia. Int J Clin Pharm. 2015;37:949 57. S4.1-30. Scott D, Blizzard L, Fell J, et al. Statin therapy, muscle func- tion and falls risk in community-dwelling older adults. QJM. 2009;102:625 33. S4.1-31. Thai M, Reeve E, Hilmer SN, et al. Prevalence of statin-drug interac- tions in older people: a systematic review. Eur J Clin Pharmacol. 2016;72:513 21. S4.1-32. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956 64. S4.1-33. Houx PJ, Shepherd J, Blauw GJ, et al. Testing cognitive function in elderly populations: the PROSPER study.


Houx PJ, Shepherd J, Blauw GJ, et al. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry. 2002;73:385 9. S4.1-34. Rodriguez F, Maron DJ, Knowles JW, et al. Association between intensity of statin therapy and mortality in patients with atheroscle- rotic cardiovascular disease. JAMA Cardiol. 2017;2:47 54. S4.1-35. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77:556 63. S4.1-36. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cogni- tive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257:85 90. S4.1-37. Feinstein MJ, Jhund P, Kang J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail. 2015;17:434 41. S4.1-38. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248 61. S4.1-39. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231 9. S4.1-40. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349 57. S4.1-41. Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137:338 50. S4.1-42. Cannon CP, Khan I, Klimchak AC, et al.


2018;137:338 50. S4.1-42. Cannon CP, Khan I, Klimchak AC, et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardio- vascular disease. JAMA Cardiol. 2017;2:959 66. S4.1-43. Virani SS, Akeroyd JM, Nambi V, et al. Estimation of eligibility for pro- protein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): insights from the Department of Veterans Affairs. Circulation. 2017;135:2572 4. S4.1-44. Bohula EA, Bonaca MP, Braunwald E, et al. Atherothrombotic risk sStratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarc- tion. Circulation. 2016;134:304 13. S4.1-45. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study) Am J Cardiol. 2009;103:577 82. S4.1-46. Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail. 2014;2:289 97. S4.1-47. Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54:1850 9. 4.2. Severe Hypercholesterolemia (LDL-C 190 mg/dL [ 4.9 mmol/L]) S4.2-1. Besseling J, Hovingh GK, Huijgen R, et al. Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. J Am Coll Cardiol. 2016;68:252 60. S4.2-2. Khera AV, Won HH, Peloso GM, et al.


2016;68:252 60. S4.2-2. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical util- ity of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67:2578 89. S4.2-3. Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698 709. S4.2-4. Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of athero- sclerotic cardiovascular disease in US adults with the familial hyper- cholesterolemia phenotype. Circulation. 2016;134:9 19. S4.2-5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301 7. S4.2-6. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. S4.2-7. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S4.2-8. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 97. CLINICAL STATEMENTS AND GUIDELINES S4.2-9. Silverman MG, Ference BA, Im K, et al. Association between lower- ing LDL-C and cardiovascular risk reduction among different thera- peutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289 97. S4.2-10. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or with- out ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431 43. S4.2-11. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to com- bination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double- blind, controlled trial. Clin Ther. 2010;32:615 25. S4.2-12.


Colesevelam added to com- bination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double- blind, controlled trial. Clin Ther. 2010;32:615 25. S4.2-12. Ross S, D Mello M, Anand SS, et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circ Cardiovasc Genet. 2015;8:618 27. S4.2-13. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996 3003. S4.2-14. Perez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135:2133 44. S4.2-15. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evo- locumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331 40. S4.2-16. Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosu- vastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69 76. S4.2-17. Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to- moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176:1834 42. S4.2-18. Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412 21. S4.2-19. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipo- protein cholesterol lowering for the primary prevention of cardio- vascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. 2017;136:1878 91. S4.2-20. Bohula EA, Morrow DA, Giugliano RP, et al.


2017;136:1878 91. S4.2-20. Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol. 2017;69:911 21. 4.3. Diabetes Mellitus in Adults S4.3-1. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary preven- tion of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685 96. S4.3-2. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005 16. S4.3-3. de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72:2365 73. S4.3-4. Knopp RH, d Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in sub- jects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabe- tes mellitus (ASPEN) Diabetes care. 2006;29:1478 85. S4.3-5. Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarc- tion in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia. 2008;51:1639 45. S4.3-6. Rana JS, Liu JY, Moffet HH, et al. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med. 2016;31:387 93. S4.3-7. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA) Diabetes Ccare. 2005;28:1151 7. S4.3-8. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al.


2005;28:1151 7. S4.3-8. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of car- diovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29:798 804. S4.3-9. Wong ND, Glovaci D, Wong K, et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res. 2012;9:146 52. S4.3-10. Karmali KN, Goff DC Jr, Ning H, et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for athero- sclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959 68. S4.3-11. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406 15. S4.3-12. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S4.3-13. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive pro- tein. N Engl J Med. 2008;359:2195 207. S4.3-14. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 97. S4.3-15. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181 92. S4.3-16. Brownrigg JR, de Lusignan S, McGovern A, et al. Peripheral neu- ropathy and the risk of cardiovascular events in type 2 diabetes mel- litus. Heart. 2014;100:1837 43. S4.3-17. Constantino MI, Molyneaux L, Limacher-Gisler F, et al.


2014;100:1837 43. S4.3-17. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 dia- betes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36:3863 9. S4.3-18. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and ado- lescence with complications during teenage years and young adult- hood. JAMA. 2017;317:825 35. S4.3-19. Guo VY, Cao B, Wu X, et al. Prospective association between dia- betic retinopathy and cardiovascular disease a systematic review and meta-analysis of cohort studies. J Stroke Cerebrovasc Dis. 2016;25:1688 95. S4.3-20. Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross- sectional study. Lancet Diabetes Endocrinol. 2016;4:115 24. S4.3-21. Nezarat N, Budoff MJ, Luo Y, et al. Presence, characteristics, and volumes of coronary plaque determined by computed tomogra- phy angiography in young type 2 diabetes mellitus. Am J Cardiol. 2017;119:1566 71. S4.3-22. Ogren M, Hedblad B, Engstrom G, et al. Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year- old men with diabetes. Results from the population study Men born in 1914 from Malmo, Sweden. Eur J Vasc Endovasc Surg. 2005;29:182 9. S4.3-23. Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55:1463 9. S4.3-24. Pang XH, Han J, Ye WL, et al. Lower extremity peripheral arterial disease is an independent predictor of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus in China. Int J Endocrinol. 2017;2017:9620513. S4.3-25. Svensson MK, Cederholm J, Eliasson B, et al.


2017;2017:9620513. S4.3-25. Svensson MK, Cederholm J, Eliasson B, et al. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diab Vasc Dis Res. 2013;10:520 9. S4.3-26. Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the con- temporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135:1979 81. S4.3-27. Silverman MG, Ference BA, Im K, et al. Association between lower- ing LDL-C and cardiovascular risk reduction among different thera- peutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289 97. CLINICAL STATEMENTS AND GUIDELINES S4.3-28. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 97. 4.4. Primary Prevention S4.4-1. Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA) Eur Heart J. 2018;39:2401 8. S4.4-2. Avorn J. The psychology of clinical decision making implications for medication use. N Engl J Med. 2018;378:689 91. S4.4-3. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92 125. S4.4-4. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the man- agement of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.


2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the man- agement of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70:1785 822. S4.4-5. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406 15. S4.4-6. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76 99. S4.4-7. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102 38. S4.4-8. US Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. Available at: https://health.gov/ paguidelines/pdf/paguide.pdf. Accessed August 24, 2018. S4.4-9. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279 90. S4.4-10. Agriculture. 2015 2020 Dietary Guidelines for Americans. 8th ed. 2015. US Department of Health and Human Services and US Department of, 2015. Available at: http://health.gov/dietary guidelines/2015/guidelines/. Accessed August 24, 2018. S4.4-11. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006 Arterioscler Thromb Vasc Biol. 2006;26:2186 91. S4.4-12. Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998;18:441 9. S4.4-13. Dehghan M, Mente A, Zhang X, et al.


1998;18:441 9. S4.4-13. Dehghan M, Mente A, Zhang X, et al. Associations of fats and car- bohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390:2050 62. S4.4-14. Chen M, Li Y, Sun Q, et al. Dairy fat and risk of cardiovascular dis- ease in 3 cohorts of US adults. Am J Clin Nutr. 2016;104:1209 17. S4.4-15. Loria CM, Liu K, Lewis CE, et al. Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study. J Am Coll Cardiol. 2007;49:2013 20. S4.4-16. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391 9. S4.4-17. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds. Geneva, Switzerland: World Health Organization. 2009. S4.4-18. Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part A: executive sum- mary. Nutr Rev. 2009;67:114 20. S4.4-19. Warburton DE, Charlesworth S, Ivey A, et al. A systematic review of the evidence for Canada s Physical Activity Guidelines for Adults. Int J Behav Nutr Phys Act. 2010;7:39. S4.4-20. Shiroma EJ, Lee IM. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010;122:743 52. S4.4-21. Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease: a meta-analy- sis. Circulation. 2011;124:789 95. 4.4.1. Evaluation and Risk Assessment 4.4.1.1. Essential Process of Risk Assessment S4.4.1.1-1. American College of Cardiology. ASCVD Risk Predictor Plus. Available at: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/ calculate/estimate/. Accessed September 1, 2018. S4.4.1.1-2. American Heart Association. ASCVD-Risk-Calculator. Available at: https://professional.heart.org/professional/GuidelinesStatements/ ASCVDRiskCalculator/UCM_457698_ASCVD-Risk-Calculator.jsp. Accessed September 1, 2018. S4.4.1.1-3. Karp I, Abrahamowicz M, Bartlett G, et al.


Accessed September 1, 2018. S4.4.1.1-3. Karp I, Abrahamowicz M, Bartlett G, et al. Updated risk factor values and the ability of the multivariable risk score to predict coronary heart disease. Am J Epidemiol. 2004;160:707 16. S4.4.1.1-4. Pencina MJ, D Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078 84. 4.4.1.2. Pooled Cohort Equations S4.4.1.2-1. DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibra- tion and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266 75. S4.4.1.2-2. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311:1416 23. S4.4.1.2-3. Wolfson J, Vock DM, Bandyopadhyay S, et al. Use and custom- ization of risk scores for predicting cardiovascular events using electronic health record data. J Am Heart Assoc 2017;6;e003670. S4.4.1.2-4. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49 73. S4.4.1.2-5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.4.1.2-6. JBS3 Board. Joint British Societies consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart 2014; 100 suppl 2. ii1 67. S4.4.1.2-7. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equa- tions. JAMA. 2014;311:1406 15. S4.4.1.2-8. Andersson C, Enserro D, Larson MG, et al.


2014;311:1406 15. S4.4.1.2-8. Andersson C, Enserro D, Larson MG, et al. Implications of the US cholesterol guidelines on eligibility for statin therapy in the commu- nity: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4:e001888. S4.4.1.2-9. Colantonio LD, Richman JS, Carson AP, et al. Performance of the atherosclerotic cardiovascular disease pooled cohort risk equations by social deprivation status. J Am Heart Assoc. 2017;6:e005676. S4.4.1.2-10. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underas- certainment in the Women s Health Study. JAMA Intern Med. 2014;174:1964 71. S4.4.1.2-11. Dalton JE, Perzynski AT, Zidar DA, et al. Accuracy of cardiovascular risk prediction varies by neighborhood socioeconomic position: a retrospective cohort study. Ann Intern Med. 2017;167:456 64. S4.4.1.2-12. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.4.1.2-13. Flueckiger P, Qureshi W, Michos ED, et al. Guideline-based statin/lipid- lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: the Multi- Ethnic Study of Atherosclerosis (MESA). Clin Cardiol. 2017;40:163 9. CLINICAL STATEMENTS AND GUIDELINES S4.4.1.2-14. Loprinzi PD, Addoh O. Predictive validity of the American College of Cardiology/American Heart Association pooled cohort equa- tions in predicting all-cause and cardiovascular disease-specific mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc. 2016;91:763 9. S4.4.1.2-15. Mortensen MB, Afzal S, Nordestgaard BG, et al. Primary preven- tion with statins: ACC/AHA risk-based approach versus trial- based approaches to guide statin therapy. J Am Coll Cardiol. 2015;66:2699 709. S4.4.1.2-16. Mortensen MB, Nordestgaard BG, Afzal S, et al.


2015;66:2699 709. S4.4.1.2-16. Mortensen MB, Nordestgaard BG, Afzal S, et al. ACC/AHA guide- lines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Eur Heart J. 2017;38:586 94. S4.4.1.2-17. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coro- nary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66:1657 68. S4.4.1.2-18. Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the ath- erosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67:2118 30. S4.4.1.2-19. Ungprasert P, Matteson EL, Crowson CS. Reliability of cardio- vascular risk calculators to estimate accurately the risk of car- diovascular disease in patients with sarcoidosis. Am J Cardiol. 2017;120:868 73. S4.4.1.2-20. Pencina MJ, D Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078 84. S4.4.1.2-21. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791 8. 4.4.1.3. Risk-Enhancing Factors S4.4.1.3-1. American College of Cardiology. ASCVD Risk Predictor Plus. Available at: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/ calculate/estimate/. Accessed September 1, 2018. S4.4.1.3-2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.4.1.3-3. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. 4.4.1.4. Coronary Artery Calcium S4.4.1.4-1. Nasir K, Bittencourt MS, Blaha MJ, et al.


Coronary Artery Calcium S4.4.1.4-1. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coro- nary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol. 2015;66:1657 68. S4.4.1.4-2. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391 9. S4.4.1.4-3. Han D, O Hartaigh B, Lee JH, et al. Assessment of coronary artery calcium scoring for statin treatment strategy according to ACC/ AHA guidelines in asymptomatic Korean adults. Yonsei Med J. 2017;58:82 9. S4.4.1.4-4. Hong JC, Blankstein R, Blaha M, et al. Cost-effectiveness of coro- nary artery calcium testing among statin candidates according to the American College of Cardiology and American Heart Association cholesterol guidelines. J Am Coll Cardiol 2017;69 11 suppl:1828. S4.4.1.4-5. Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img. 2017;10:143 53. S4.4.1.4-6. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease- guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol. 2016;68:881 91. S4.4.1.4-7. Pursnani A, Massaro JM, D Agostino RB Sr, et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. 2015;314:134 41. S4.4.1.4-8. Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. Circulation. 2015;132:916 22. S4.4.1.4-9. Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA) Am Heart J.


Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA) Am Heart J. 2009;158:554 61. S4.4.1.4-10. McEvoy JW, Blaha MJ, Rivera JJ, et al. Mortality rates in smokers and nonsmokers in the presence or absence of coronary artery calcification. J Am Coll Cardiol Img. 2012;5:1037 45. S4.4.1.4-11. Cohen R, Budoff M, McClelland RL, et al. Significance of a posi- tive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the Multi-Ethnic Study of Atherosclerosis) Am J Cardiol. 2014;114:1210 14. S4.4.1.4-12. Metkus TS, Brown T, Budoff M, et al. HIV infection is associated with an increased prevalence of coronary noncalcified plaque among participants with a coronary artery calcium score of zero: Multicenter AIDS Cohort Study (MACS) HIV Med. 2015;16:635 9. S4.4.1.4-13. Budoff MJ, Young R, Burke G, et al. Ten-year association of coro- nary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA) Eur Heart J. 2018;39:2401 8. S4.4.1.4-14. Valenti V, B OH, Heo R, et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a pro- spective follow-Up of 9715 individuals. J Am Coll Cardiol Img. 2015;8:900 9. S4.4.1.4-15. Lehmann N, Erbel R, Mahabadi AA, et al. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR Study (Heinz Nixdorf Recall) Circulation. 2018;137:665 79. S4.4.1.4-16. Alluri K, McEvoy JW, Dardari ZA, et al. Distribution and burden of newly detected coronary artery calcium: results from the Multi- Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2015;9:337 344 e1. S4.4.1.4-17. Lee S-E, Chang H-J, Sung JM, et al. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. J Am Coll Cardiol Img. 2018;11:1475 84. S4.4.1.4-18. Rozanski A, Gransar H, Shaw LJ, et al.


2018;11:1475 84. S4.4.1.4-18. Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream test- ing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011;57:1622 32. S4.4.1.4-19. Chevalier M, Moran P, Ten JI, et al. Patient dose in digital mam- mography. Med Phys. 2004;31:2471 9. 4.4.2. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL S4.4.2-1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S4.4.2-2. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181 92. S4.4.2-3. Cholesterol Treatment Trialists (CTT) Collaboration, Herrington W, Emberson J, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829 39. S4.4.2-4. Chou R, Dana T, Blazina I, et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force. Rockville, MD: US Agency for Healthcare Research and Quality, 2016. Report No.: 14-05206-EF-2. S4.4.2-5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Jama. 1998;279:1615 22. S4.4.2-6. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive pro- tein. N Engl J Med.


Rosuvastatin to prevent vascular events in men and women with elevated C-reactive pro- tein. N Engl J Med. 2008;359:2195 207. CLINICAL STATEMENTS AND GUIDELINES S4.4.2-7. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013:CD004816. S4.4.2-8. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in inter- mediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. S4.4.2-9. Silverman MG, Ference BA, Im K, et al. Association between lower- ing LDL-C and cardiovascular risk reduction among different thera- peutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289 97. S4.4.2-10. Karmali KN, Goff DC Jr, Ning H, et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for athero- sclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:959 68. S4.4.2-11. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406 15. S4.4.2-12. Krumholz HM. Treatment of cholesterol in 2017. JAMA. 2017;318:417 8. S4.4.2-13. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discus- sion for atherosclerotic cardiovascular disease prevention: impor- tance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65:1361 8. S4.4.2-14. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431. S4.4.2-15. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease- guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol. 2016;68:881 91. S4.4.2-16. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospec- tive 15-year outcomes in the Bruneck study. J Am Coll Cardiol. 2014;64:851 60. S4.4.2-17. Nasir K, Bittencourt MS, Blaha MJ, et al.


2014;64:851 60. S4.4.2-17. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coro- nary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol. 2015;66:1657 68. S4.4.2-18. Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37:1373 9. S4.4.2-19. Yano Y, O Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol. 2017;2:986 94. S4.4.2-20. Malik S, Zhao Y, Budoff M, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2017;2:1332 40. S4.4.2-21. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging thera- pies. J Am Coll Cardiol. 2014;63:1935 47. S4.4.2-22. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337 45. S4.4.2-23. Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA) Eur Heart J. 2018;39:2401 8. S4.4.2-24. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581 90. S4.4.2-25. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368: 1155 63.


Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368: 1155 63. S4.4.2-26. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.4.2-27. Navar AM, Stone NJ, Martin SS. What to say and how to say it: effective communication for cardiovascular disease prevention. Curr Opin Cardiol. 2016;31:537 44. S4.4.2-28. Laing ST. High-intensity statins: guideline expectations and clinical application. JAMA. 2017;317:2543 4. S4.4.2-29. Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175 6. S4.4.2-30. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardio- vascular risk, is important in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975 83. S4.4.2-31. Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardio- vascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340 6. S4.4.2-32. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.4.2-33. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guide- line on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73. S4.4.2-34. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA) Circulation. 2016;133:849 58. S4.4.2-35.


Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA) Circulation. 2016;133:849 58. S4.4.2-35. Cohen R, Budoff M, McClelland RL, et al. Significance of a posi- tive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the Multi-Ethnic Study of Atherosclerosis) Am J Cardiol. 2014;114:1210 4. S4.4.2-36. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391 9. S4.4.2-37. Fudim M, Zalawadiya S, Patel DK, et al. Data on coronary artery calcium score performance and cardiovascular risk reclassification across gender and ethnicities. Data Brief. 2016;6:578 81. S4.4.2-38. Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. J Am Coll Cardiol Img. 2017;10:833 42. S4.4.2-39. Han D, O Hartaigh B, Lee JH, et al. Assessment of coronary artery calcium scoring for statin treatment strategy according to ACC/ AHA guidelines in asymptomatic Korean adults. Yonsei Med J. 2017;58:82 9. S4.4.2-40. Hong JC, Blankstein R, Blaha M, et al. Cost-effectiveness of coronary artery calcium testing among statin candidates according to the American College of Cardiology and American Heart Association cholesterol guidelines. J Am Coll Cardiol 2017;69 11 suppl:1828. S4.4.2-41. Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. JAMA. 2016;316:2126 34. S4.4.2-42. Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img. 2017;10:143 53. S4.4.2-43.


CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img. 2017;10:143 53. S4.4.2-43. McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study) J Am Coll Cardiol. 2015;66:1643 53. S4.4.2-44. Pursnani A, Massaro JM, D Agostino RB Sr, et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. 2015;314:134 41. S4.4.2-45. Qureshi WT, Rana JS, Yeboah J, et al. Risk stratification for primary prevention of coronary artery disease: roles of C-reactive protein and coronary artery calcium. Curr Cardiol Rep. 2015;17:110. S4.4.2-46. Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical atherosclero- sis, statin eligibility, and outcomes in African American individuals: the Jackson Heart study. JAMA Cardiol. 2017;2:644 52. S4.4.2-47. Waheed S, Pollack S, Roth M, et al. Collective impact of conven- tional cardiovascular risk factors and coronary calcium score on clini- cal outcomes with or without statin therapy: the St Francis Heart Study. Atherosclerosis. 2016;255:193 9. CLINICAL STATEMENTS AND GUIDELINES S4.4.2-48. Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. Circulation. 2015;132:916 22. S4.4.2-49. Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assess- ment. J Am Coll Cardiol. 2016;67:139 47. S4.4.2-50. Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA) Am Heart J. 2009;158:554 61. S4.4.2-51. Schulman-Marcus J, Valenti V, Hartaigh BO, et al.


2009;158:554 61. S4.4.2-51. Schulman-Marcus J, Valenti V, Hartaigh BO, et al. Prognostic util- ity of coronary artery calcium scoring in active smokers: a 15-year follow-up study. Int J Cardiol. 2014;177:581 3. S4.4.2 52. Valenti V, Hartaigh BO, Cho I, et al. Absence of coronary artery cal- cium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients. Circ Cardiovasc Imaging 2016;9:e003528. S4.4.2 53. Patel J, Al Rifai M, Blaha MJ, et al. Coronary artery calcium improves risk assessment in adults with a family history of pre- mature coronary heart disease: results from Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2015:8;e003186. S4.4.2-54. Sharp Collaborative Group null. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lower- ing low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. Am Heart J. 2010;160:785 94; e10. S4.4.2-55. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351 64. S4.4.2-56. Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipid- emia. Ann Intern Med. 1995;123:493 9. S4.4.2-57. Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314:142 50. S4.4.2-58. Singh A, Collins BL, Gupta A, et al. Cardiovascular risk and statin eligibility of young adults after an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71:292 302. S4.4.2-59. Navar-Boggan AM, Peterson ED, D Agostino RB Sr, et al. Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all. J Am Coll Cardiol. 2015;65:1633 9. S4.4.2-60. The Lipid Research Clinics Coronary Primary Prevention Trial results. II.


The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart dis- ease to cholesterol lowering. JAMA. 1984;251:365 74. 4.4.3. Monitoring in Response to LDL-C Lowering Therapy S4.4.3-1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.4.3-2. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004:22 suppl 3:13 23. S4.4.3-3. Chiavaroli L, Nishi SK, Khan TA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials. Prog Cardiovasc Dis. 2018;61:43 53. 4.4.4. Primary Prevention in Other Age Groups 4.4.4.1. Older Adults S4.4.4.1-1. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive pro- tein and low to average low-density lipoprotein cholesterol lev- els: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488 96. w174. S4.4.4.1-2. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive pro- tein. N Engl J Med. 2008;359:2195 207. S4.4.4.1-3. Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the con- temporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135:1979 81. S4.4.4.1-4. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. S4.4.4.1-5. Orkaby AR, Gaziano JM, Djousse L, et al. Statins for primary pre- vention of cardiovascular events and mortality in older men. J Am Geriatr Soc. 2017;65:2362 8. S4.4.4.1-6.


Statins for primary pre- vention of cardiovascular events and mortality in older men. J Am Geriatr Soc. 2017;65:2362 8. S4.4.4.1-6. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lower- ing LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 ran- domised trials. Lancet. 2012;380:581 90. S4.4.4.1-7. Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090 9. S4.4.4.1-8. Teng M, Lin L, Zhao YJ, et al. Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging. 2015;32:649 61. S4.4.4.1-9. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life- limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175:691 700. S4.4.4.1-10. Mahabadi AA, Mohlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img. 2017;10:143 53. S4.4.4.1-11. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease- guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol. 2016;68:881 91. S4.4.4.1-12. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623 30. S4.4.4.1-13. Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85 94. S4.4.4.1-14. Bell SP, Orr NM, Dodson JA, et al. What to expect from the evolving field of geriatric cardiology. J Am Coll Cardiol. 2015;66:1286 99. S4.4.4.1-15. Fleg JL, Forman DE, Berra K, et al.


2015;66:1286 99. S4.4.4.1-15. Fleg JL, Forman DE, Berra K, et al. Secondary prevention of ath- erosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013;128:2422 46. S4.4.4.1-16. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf. 2015;6:212 33. S4.4.4.1-17. Qi K, Reeve E, Hilmer SN, et al. Older peoples attitudes regarding polypharmacy, statin use and willingness to have statins depre- scribed in Australia. Int J Clin Pharm. 2015;37:949 57. S4.4.4.1-18. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascu- lar drugs: challenges for research and for patient care. J Am Coll Cardiol. 2015;66:1273 85. S4.4.4.1-19. Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177:955 65. S4.4.4.1-20. Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 yearsorolderintheUnitedStates.AnnInternMed.2015;162:533 41. 4.4.4.2. Young Adults (20 to 39 Years of Age) S4.4.4.2-1. Strong JP, Malcom GT, Oalmann MC, et al. The PDAY Study: natural history, risk factors, and pathobiology. Pathobiological Determinants of Atherosclerosis in Youth. Ann N Y Acad Sci. 1997;811:226 35.; discussion 35 7. S4.4.4.2-2. McGill HC Jr, McMahan CA, Herderick EE, et al. Effects of coro- nary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 2000;20:836 45. S4.4.4.2-3. Williams RR, Hopkins PN, Hunt SC, et al. Population-based fre- quency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med. 1990;150:582 8. S4.4.4.2-4. McGill HC Jr, McMahan CA, Malcom GT, et al.


S4.4.4.2-4. McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997;17:95 106. CLINICAL STATEMENTS AND GUIDELINES S4.4.4.2-5. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipid- emia. Am J Cardiol. 2012;110:823 5. S4.4.4.2-6. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med. 2003;163:1966 72. S4.4.4.2-7. Domanski M, Lloyd-Jones D, Fuster V, et al. Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721 5. S4.4.4.2-8. Durrington PN, Soran H. Cholesterol levels should play a more important role in identifying statin recipients. Circulation. 2017;135:627 9. S4.4.4.2-9. Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of cardiovascular disease: an opportunity to har- monize guidelines. JAMA Cardiol. 2017;2:1175 6. S4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular dis- ease. N Engl J Med. 2012;366:321 9. S4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505 6. S4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers awareness of physical activity-related intensive behavioral coun- seling services for cardiovascular disease prevention. Am J Health Promot. 2018. 890117118784226. S4.4.4.2-13. Domanski MJ, Fuster V, Diaz-Mitoma F, et al. Next steps in primary prevention of coronary heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66:1828 36. S4.4.4.2-14. Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391 9. 4.4.4.3. Children and Adolescents S4.4.4.3-1.


Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391 9. 4.4.4.3. Children and Adolescents S4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419 24. S4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise inter- vention using Dance Dance Revolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes. 2009;4:205 14. S4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol. 2014;8:181 6. S4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015;23:2109 17. S4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;116:1032 40. S4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC) Pediatrics. 2001;107:256 64. S4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. 2011;96:E1999 2008. S4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyper- lipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708 13. S4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipid- emia and standardized lifestyle modification: benchmarking real- world practice.


Adolescent dyslipid- emia and standardized lifestyle modification: benchmarking real- world practice. J Am Coll Cardiol. 2016;68:2122 3. S4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associ- ated with an improved lipid profile in children with familial hyper- cholesterolemia. Atherosclerosis. 2016;252:21 7. S4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterol- emia in children and adolescents. Acta Paediatr. 1992;81:682 5. S4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for hypercholesterolemic chil- dren. Am J Public Health. 1998;88:258 61. S4.4.4.3-13. Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166:1377 84 e1-3. S4.4.4.3-14. Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adoles- cents. J Pediatr Endocrinol Metab. 2009;22:487 92. S4.4.4.3-15. Clauss S, Wai KM, Kavey RE, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869 72. S4.4.4.3-16. Sonnett T, Robinson J, Milani P, et al. Role of colesevelam in man- aging heterozygous familial hypercholesterolemia in adolescents and children. Adolesc Health Med Ther. 2010;1:53 60. S4.4.4.3-17. Wald DS, Kasturiratne A, Godoy A, et al. Child-parent screening for familial hypercholesterolemia. J Pediatr. 2011;159:865 7. S4.4.4.3-18. Wald DS, Bestwick JP, Morris JK, et al. Child-parent familial hypercholesterolemia screening in primary care. N Engl J Med. 2016;375:1628 37. S4.4.4.3-19. Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. Pediatrics. 2010;126:260 5. S4.4.4.3-20. Skovby F, Micic S, Jepsen B, et al. Screening for familial hyper- cholesterolaemia by measurement of apolipoproteins in capillary blood. Arch Dis Child. 1991;66:844 7. S4.4.4.3-21. Garcia RE, Moodie DS. Routine cholesterol surveillance in child- hood. Pediatrics. 1989;84:751 5. S4.4.4.3-22. Ned RM, Sijbrands EJ.


Routine cholesterol surveillance in child- hood. Pediatrics. 1989;84:751 5. S4.4.4.3-22. Ned RM, Sijbrands EJ. Cascade screening for familial hypercholes- terolemia (FH) PLoS Curr. 2011;3:RRN1238. S4.4.4.3-23. Bender R, Bell DA, Hooper AJ, et al. Screening for familial hyper- cholesterolaemia. Pathology. 2012;44:122 8. S4.4.4.3-24. National Institute for Health and Care Excellence (NICE) (UK). Familial hypercholesterolaemia: identification and management. Available at: http://www.nice.org.uk/guidance/CG71. Accessed August 24, 2018. S4.4.4.3-25. Kit BK, Kuklina E, Carroll MD, et al. Prevalence of and trends in dyslipidemia and blood pressure among US children and adoles- cents, 1999 2012 JAMA Pediatr. 2015;169:272 9. S4.4.4.3-26. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular dis- ease risk factors among US adolescents, 1999 2008 Pediatrics. 2012;129:1035 41. S4.4.4.3-27. Lozano P, Henrikson NB, Morrison CC, et al. Lipid screening in childhood and adolescence for detection of multifactorial dys- lipidemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:634 44. S4.4.4.3-28. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167 92. S4.4.4.3-29. Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in child- hood and adolescence for detection of familial hypercholesterol- emia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:645 55. S4.4.4.3-30. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2017;7:CD006401. S4.4.4.3-31. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvas- tatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64:285 96. S4.4.4.3-32. Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis pro- gression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557 66. S4.4.4.3-33.


Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis pro- gression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557 66. S4.4.4.3-33. Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of ath- erosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation. 2016;134:9 19. S4.4.4.3-34. Neil HA, Hawkins MM, Durrington PN, et al. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective regis- try study. Atherosclerosis. 2005;179:293 7. S4.4.4.3-35. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterol- emia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935 47. S4.4.4.3-36. Smith AJ, Turner EL, Kinra S. Universal cholesterol screening in childhood: a systematic review. Acad Pediatr. 2016;16:716 25. S4.4.4.3-37. Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38:1832 9. CLINICAL STATEMENTS AND GUIDELINES S4.4.4.3-38. Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol. 2002;90:3L 7L. S4.4.4.3-39. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima- media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation. 2010;122:2514 20. S4.4.4.3-40. Juhola J, Magnussen CG, Viikari JS, et al. Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. J Pediatr. 2011;159:584 90. S4.4.4.3-41.


Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. J Pediatr. 2011;159:584 90. S4.4.4.3-41. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guide- lines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128 suppl 5: S213 56. S4.4.4.3-42. Gidding SS, Daniels SR, Kavey RE, et al. Developing the 2011 integrated pediatric guidelines for cardiovascular risk reduction. Pediatrics. 2012;129:e1311 9. 4.5. Other Populations at Risk S4.5.1-1. Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393 423. abnormalities among normal-weight persons from five racial/eth- nic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med. 2017;166:628 36. S4.5.1-3. Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse popula- tions: a scientific statement from the American Heart Association. Circulation. 2015;132:457 72. S4.5.1-4. Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J. 2013;77:1923 32. S4.5.1-5. Group H-TC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279 91. S4.5.1-6. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.5.1-7.


Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.5.1-7. Daviglus ML, Pirzada A, Talavera GA. Cardiovascular disease risk factors in the Hispanic/Latino population: lessons from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Prog Cardiovasc Dis. 2014;57:230 6. S4.5.1-8. Daviglus ML, Pirzada A, Durazo-Arvizu R, et al. Prevalence of low cardiovascular risk profile among diverse Hispanic/Latino adults in the United States by age, sex, and level of tacculturation: the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc 2016;5:e003929. S4.5.1-9. Gonzalez HM, Tarraf W, Rodriguez CJ, et al. Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results. Am Heart J. 2016;176:134 44. S4.5.1-10. Qureshi WT, Kaplan RC, Swett K, et al. American College of Cardiology/American Heart Association (ACC/AHA) Class I guidelines for the treatment of cholesterol to reduce ath- erosclerotic cardiovascular risk: implications for US Hispanics/ Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) J Am Heart Assoc 2017:6; e005045. S4.5.1-11. Schneiderman N, Chirinos DA, Aviles-Santa ML, et al. Challenges in preventing heart disease in hispanics: early lessons learned from the Hispanic Community Health Study/Study of Latinos (HCHS/ SOL) Prog Cardiovasc Dis. 2014;57:253 61. S4.5.1-12. Hutchinson RN, Shin S. Systematic review of health disparities for cardiovascular diseases and associated factors among American Indian and Alaska Native populations. PLoS One. 2014:9;e80973. S4.5.1-13. Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epide- miology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation. 2018;138:e1 34. S4.5.1-14. Conomos MP, Laurie CA, Stilp AM, et al.


2018;138:e1 34. S4.5.1-14. Conomos MP, Laurie CA, Stilp AM, et al. Genetic diversity and asso- ciation studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet. 2016;98:165 84. S4.5.1-15. Frank AT, Zhao B, Jose PO, et al. Racial/ethnic differences in dyslipid- emia patterns. Circulation. 2014;129:570 9. S4.5.1-16. Pu J, Romanelli R, Zhao B, et al. Dyslipidemia in special ethnic popu- lations. Cardiol Clin. 2015;33:325 33. S4.5.1-17. Basu S, Hong A, Siddiqi A. Using decomposition analysis to identify modifiable racial disparities in the distribution of blood pressure in the United States. Am J Epidemiol. 2015;182:345 53. S4.5.1-18. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syn- drome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180 93. S4.5.1-19. Gujral UP, Pradeepa R, Weber MB, et al. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281:51 63. S4.5.1-20. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and dif- ferences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64 91. S4.5.1-21. Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988 2012 JAMA. 2015;314:1021 9. S4.5.1-22. DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive thera- pies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38:598 608. S4.5.1-23. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.


2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49 73. S4.5.1-24. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406 15. S4.5.1-25. Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atheroscle- rotic cardiovascular risk equation in a large contemporary, multieth- nic population. J Am Coll Cardiol. 2016;67:2118 30. S4.5.1 26. Kandula NR, Kanaya AM, Liu K, et al. Association of 10-year and lifetime predicted cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. J Am Heart Assoc. 2014:3;e001117. S4.5.1-27. Alluri K, McEvoy JW, Dardari ZA, et al. Distribution and burden of newly detected coronary artery calcium: results from the Multi- Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2015;9:337 344.e1. S4.5.1 28. Cho YK, Jung CH, Kang YM, et al. 2013 ACC/AHA cholesterol guideline versus 2004 NCEP ATP III guideline in the prediction of coronary artery calcification progression in a Korean Population. J Am Heart Assoc 2016;5:e003410. S4.5.1-29. Manolio TA, Arnold AM, Post W, et al. Ethnic differences in the relationship of carotid atherosclerosis to coronary calcifica- tion: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;197:132 8. S4.5.1-30. Osawa K, Nakanishi R, Budoff M. Coronary artery calcification. Glob Heart. 2016;11:287 93. S4.5.1-31. Kanaya AM, Kandula NR, Ewing SK, et al. Comparing coronary artery calcium among US South Asians with four racial/ethnic groups: the MASALA and MESA studies. Atherosclerosis. 2014;234:102 7. S4.5.1-32. Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72:434 47. S4.5.1-33. Nakamura H, Arakawa K, Itakura H, et al.


2018;72:434 47. S4.5.1-33. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of car- diovascular disease with pravastatin in Japan (MEGA Study): a pro- spective randomised controlled trial. Lancet. 2006;368:1155 63. S4.5.1-34. Kimura T, Inoue T, Taguchi I, et al. Does high-intensity pitavastatin therapy further improve clinical outcomes? The REAL-CAD study CLINICAL STATEMENTS AND GUIDELINES in 13054 patients with stable coronary artery disease. Circulation 2017:136;e450. S4.5.1-35. Birmingham BK, Bujac SR, Elsby R, et al. Rosuvastatin pharmacoki- netics and pharmacogenetics in Caucasian and Asian subjects resid- ing in the United States. Eur J Clin Pharmacol. 2015;71:329 40. S4.5.1-36. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330 41. S4.5.1-37. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410 4. S4.5.1-38. Lloret R, Ycas J, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial) Am J Cardiol. 2006;98:768 73. S4.5.1-39. George MD, McGill NK, Baker JF. Creatine kinase in the US popula- tion: Impact of demographics, comorbidities, and body composition on the normal range. Medicine (Baltimore). 2016;95:e4344. S4.5.2-1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.5.2-2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213 9. S4.5.2-3. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama. 2007;298:299 308. S4.5.2-4.


Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama. 2007;298:299 308. S4.5.2-4. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglyc- erides and risk of ischemic stroke in the general population. Jama. 2008;300:2142 52. S4.5.2-5. Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-anal- ysis of the impact of statin therapy on low-density lipoprotein cho- lesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444 8. S4.5.2-6. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581 90. S4.5.2-7. Christian JB, Arondekar B, Buysman EK, et al. Clinical and eco- nomic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450 61. S4.5.2-8. Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers choles- terol saturation index of gallbladder bile. Hepatology. 1988;8: 1147 50. S4.5.2-9. Rhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutri- tion therapy is the essential cornerstone for effective treatment of refractory severe hypertriglyceridemia regardless of pharmaceuti- cal treatment: evidence from a lipid management program. J Clin Lipidol. 2015;9:559 67. S4.5.2-10. Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipo- proteinemia. A descriptive study in 32 families. Ann Intern Med. 1977;87:526 34. S4.5.2-11. Steiner G, Adelman AG, Silver MD. Early coronary atheroscle- rosis in primary type V hyperlipoproteinemia. Can Med Assoc J. 1971;105:1172 4. S4.5.2-12. Neil HA, Cooper J, Betteridge DJ, et al. All-cause and cardiovas- cular mortality in treated patients with severe hypertriglyceri- daemia: a long-term prospective registry study. Atherosclerosis. 2010;211:618 23. S4.5.2-13.


All-cause and cardiovas- cular mortality in treated patients with severe hypertriglyceri- daemia: a long-term prospective registry study. Atherosclerosis. 2010;211:618 23. S4.5.2-13. Christian JB, Arondekar B, Buysman EK, et al. Determining triglycer- ide reductions needed for clinical impact in severe hypertriglyceride- mia. Am J Med. 2014;127:36 44 e1. S4.5.2-14. Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism. 1983;32:209 14. S4.5.2-15. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglycer- ide levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial) Am J Cardiol. 2011;108:682 90. S4.5.2-16. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular dis- ease: a scientific statement from the American Heart Association. Circulation. 2016;134:e468 95. S4.5.2-17. Basar R, Uzum AK, Canbaz B, et al. Therapeutic apheresis for severe hypertriglyceridemia in pregnancy. Arch Gynecol Obstet. 2013;287:839 43. 4.5.3. Issues Specific to Women S4.5.3-1. Ouyang P, Wenger NK, Taylor D, et al. Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. Biol Sex Differ. 2016;7:19. S4.5.3-2. Grandi SM, Vallee-Pouliot K, Reynier P, et al. Hypertensive disorders in pregnancy and the risk of subsequent cardiovascular disease. Paediatr Perinat Epidemiol. 2017;31:412 21. S4.5.3-3. Shostrom DCV, Sun Y, Oleson JJ, et al. History of gestational diabe- tes mellitus in relation to cardiovascular disease and cardiovascular risk factors in US women. Front Endocrinol (Lausanne). 2017;8:144. S4.5.3-4. Catov JM, Newman AB, Roberts JM, et al. Preterm delivery and later maternal cardiovascular disease risk. Epidemiology. 2007;18:733 9. S4.5.3-5. Muka T, Oliver-Williams C, Kunutsor S, et al.


2007;18:733 9. S4.5.3-5. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1:767 76. S4.5.3-6. Roeters van Lennep JE, Heida KY, Bots ML, et al. Cardiovascular dis- ease risk in women with premature ovarian insufficiency: A system- atic review and meta-analysis. Eur J Prev Cardiol. 2016;23:178 86. S4.5.3-7. Edison RJ, Muenke M. Central nervous system and limb anoma- lies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350:1579 82. S4.5.3-8. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64:496 509. S4.5.3-9. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG- CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175 7. S4.5.3-10. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013;120:463 71. S4.5.3-11. Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014;36:506 9. S4.5.3-12. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf. 2017;26:843 52. S4.5.3-13. Fulcher J, O Connell R, Voysey M, et al. Efficacy and safety of LDL- lowering therapy among men and women: meta-analysis of individ- ual data from 174000 participants in 27 randomised trials. Lancet. 2015;385:1397 405. S4.5.3 14. Ley SH, Li Y, Tobias DK, et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of car- diovascular disease in women. J Am Heart Assoc 2017;6;e006713. S4.5.3-15.


Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of car- diovascular disease in women. J Am Heart Assoc 2017;6;e006713. S4.5.3-15. Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmaco- kinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214:720.e1 e17. S4.5.3-16. Toleikyte I, Retterstol K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124:1606 14. S4.5.3-17. Sanderson SL, Iverius PH, Wilson DE. Successful hyperlipemic preg- nancy. JAMA. 1991;265:1858 60. 4.5.4 Adults With CKD S4.5.4-1. Cholesterol Treatment Trialists (CTT) Collaboration, Herrington W, Emberson J, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829 39. S4.5.4-2. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181 92. CLINICAL STATEMENTS AND GUIDELINES S4.5.4-3. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and car- diovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395 407. S4.5.4-4. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238 48. S4.5.4-5. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in peo- ple with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807 14. S4.5.4-6. Matsushita K, van der Velde M, Astor BC, et al. Association of esti- mated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collabora- tive meta-analysis. Lancet.


Association of esti- mated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collabora- tive meta-analysis. Lancet. 2010;375:2073 81. S4.5.4-7. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbumin- uria. Circulation. 2004;110:2809 16. 4.5.5. Adults With Chronic Inflammatory Disorders and HIV S4.5.5-1. Mantel A, Holmqvist M, Jernberg T, et al. Rheumatoid arthritis is asso- ciated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J. 2015;36:3413 22. S4.5.5-2. Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syn- drome. Ann Rheum Dis. 2006;65:348 53. S4.5.5-3. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70:929 34. S4.5.5-4. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovas- cular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690 7. S4.5.5-5. Wajed J, Ahmad Y, Durrington PN, et al. Prevention of cardiovascu- lar disease in systemic lupus erythematosus proposed guidelines for risk factor management. Rheumatology (Oxford). 2004;43:7 12. S4.5.5-6. Westerweel PE, Luyten RK, Koomans HA, et al. Premature athero- sclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 2007;56:1384 96. S4.5.5-7. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000 6. S4.5.5-8. Hanna DB, Ramaswamy C, Kaplan RC, et al. Trends in cardiovas- cular disease Mortality among persons with HIV in New York City, 2001 2012 Clin Infect Dis. 2016;63:1122 9. S4.5.5-9. Triant VA, Lee H, Hadigan C, et al.


2016;63:1122 9. S4.5.5-9. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506 12. S4.5.5-10. Kearns A, Gordon J, Burdo TH, et al. HIV-1-associated atherosclero- sis: unraveling the missing link. J Am Coll Cardiol. 2017;69:3084 98. S4.5.5-11. Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart. 2017;103:1867 73. S4.5.5-12. Fernandez-Montero JV, Barreiro P, de Mendoza C, et al. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47 52. S4.5.5-13. Bartels CM, Kind AJ, Everett C, et al. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:1221 30. S4.5.5-14. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for sub- stantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010;69:683 8. S4.5.5-15. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretro- viral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993 2003. S4.5.5-16. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.5.5-17. Arts EE, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74:668 74. S4.5.5-18. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insu- lin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35 43.


Hyperlipidemia and insu- lin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35 43. S4.5.5-19. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected par- ticipants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45: 111 9. S4.5.5-20. Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population- based cohort study. Arthritis Rheum. 2007;56:820 30. S4.5.5-21. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482 7. S4.5.5-22. Ronda N, Favari E, Borghi MO, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythema- tosus. Ann Rheum Dis. 2014;73:609 15. S4.5.5-23. Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65:1430 8. 5. STATIN SAFETY AND STATIN- ASSOCIATED SIDE EFFECTS S5-1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013:CD004816. S5-2. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discus- sion for atherosclerotic cardiovascular disease prevention: impor- tance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65:1361 8. S5-3. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96 103. S5-4. Gupta A, Thompson D, Whitehouse A, et al.


2013;127:96 103. S5-4. Gupta A, Thompson D, Whitehouse A, et al. Adverse events asso- ciated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389:2473 81. S5-5. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and toler- ability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580 90. S5-6. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758 69. S5-7. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301 10. S5-8. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analy- sis from the JUPITER trial. Lancet. 2012;380:565 71. S5-9. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556 64. S5-10. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735 42. S5-11. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123 30. S5-12. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metfor- min. N Engl J Med. 2002;346:393 403. S5-13. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012 22. S5-14.


Statin-associated muscle symptoms: impact on statin therapy European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012 22. S5-14. Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395 410. CLINICAL STATEMENTS AND GUIDELINES S5-15. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S5-16. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916 22. S5-17. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71 7. S5-18. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coro- nary heart disease patients with mild-to-moderate baseline eleva- tions in alanine aminotransferase levels. Int J Cardiol. 2013;168: 3846 52. S5-19. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92 125. S5-20. Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238:329 35. S5-21. Banach M, Serban C, Sahebkar A, et al.


2015;238:329 35. S5-21. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24 34. S5-22. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S5-23. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388: 2532 61. S5-24. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in inter- mediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. S5-25. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate mus- cular symptoms with high-dosage statin therapy in hyper- lipidemic patients the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403 14. S5-26. Cohen JD, Brinton EA, Ito MK, et al. Understanding statin Use in America and Gaps in Patient Education (USAGE): an Internet-based survey of 10138 current and former statin users. J Clin Lipidol. 2012;6:208 15. S5-27. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386 95. S5-28. Zhang H, Plutzky J, Shubina M, et al. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167:221 7. S5-29. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526 34. S5-30. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6 15. S5-31. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.


Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597 603. S5-32. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664 9. S5-33. Richardson K, Schoen M, French B, et al. Statins and cogni- tive function: a systematic review. Ann Intern Med. 2013;159: 688 97. S5-34. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49 73. S6-1. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111 5. S6-2. Tamblyn R, Reidel K, Huang A, et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making. 2010;30:176 88. S6-3. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combina- tion strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918 29. S6-4. van Driel ML, Morledge MD, Ulep R, et al. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016;12:CD004371. S6-5. Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI Implementation Science Work Group: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e122 37. S6-6. Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation a scoping review. Healthcare (Basel) 2016;4. S6-7.


Barriers and strategies in guideline implementation a scoping review. Healthcare (Basel) 2016;4. S6-7. Stacey D, Hill S, McCaffery K, et al. Shared decision making inter- ventions: theoretical and empirical evidence with implications for health literacy. Stud Health Technol Inform. 2017;240:263 83. S6-8. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431. S6-9. Cabana MD, Rand CS, Powe NR, et al. Why don t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458 65. S6-10. Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association cholesterol management guideline in cardiology practices nationwide. JAMA Cardiol. 2017;2:361 9. S6-11. Rodriguez F, Lin S, Maron DJ, et al. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: practice impact of the new cholesterol guide- lines. Am Heart J. 2016;182:97 102. S6-12. Pokharel Y, Gosch K, Nambi V, et al. Practice-level variation in statin use among patients with diabetes: insights from the PINNACLE Registry. J Am Coll Cardiol. 2016;68:1368 9. S6-13. Hira RS, Cowart JB, Akeroyd JM, et al. Risk factor optimization and guideline-directed medical therapy in US veterans with peripheral arterial and ischemic cerebrovascular disease compared to veterans with coronary heart disease. Am J Cardiol. 2016;118:1144 9. S6-14. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic dis- eases in the United States: a systematic review. Ann Intern Med. 2012;157:785 95. S6-15. Slejko JF, Ho M, Anderson HD, et al. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20:51 7. S6-16. Zimolzak AJ, Spettell CM, Fernandes J, et al.